Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1466]

Researchers discover how immune cells resist radiation treatment

Researchers discover how immune cells resist radiation treatment

Pembrolizumab in advanced melanoma has added benefit for certain patients

Pembrolizumab in advanced melanoma has added benefit for certain patients

Combination of pills for advanced skin cancer extends survival compared with previous monotherapy

Combination of pills for advanced skin cancer extends survival compared with previous monotherapy

Nivolumab in NSCLC: Indication of major added benefit for under 75-year-olds

Nivolumab in NSCLC: Indication of major added benefit for under 75-year-olds

Avelumab receives FDA Breakthrough Therapy Designation for Merkel cell carcinoma

Avelumab receives FDA Breakthrough Therapy Designation for Merkel cell carcinoma

FDA OKs cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib

FDA OKs cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination...

Study confirms 'intermediate' disease stage between benign moles and malignancy in melanoma

Study confirms 'intermediate' disease stage between benign moles and malignancy in melanoma

New link found in colon cancer and melanoma drug treatment

New link found in colon cancer and melanoma drug treatment

Targeted treatment produces rapid shrinkage of recurrent, BRAF-mutant brain tumour

Targeted treatment produces rapid shrinkage of recurrent, BRAF-mutant brain tumour

Confusion created by changes to the UK Cancer Drugs Fund

Confusion created by changes to the UK Cancer Drugs Fund

More from ecancer